Erythropoietin/Haematopoietin-derived peptide functions as a stroke medicine: Cyclic helix B peptide (CHBP), derived from Erythropoietin/Haematopoietin,  attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits, via up-regulation of its target genes BDNF and NAMPT, 24/April/2019, 5.56 am

Mechanistic insights into how Edaravone aids in recovery from stroke: Edaravone (brand name: Radicut, Radicava, Xavron, Edavit, others), used in the treatment of stroke and amyotrophic lateral sclerosis, increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 23/April/2019, 12.14 am
April 22, 2019
Canagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Canagliflozin (Brand name: Invokana, Sulisent, Prominad), a Sodium-glucose co-transporter 2 inhibitor used to treat TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 24/April/2019, 7.37 am
April 24, 2019
Show all

Introduction: What they say 

A recent study from Research Center for Neurobiology and Department of Neurobiology, Xuzhou Medical College, 209 Tongshan Road, Xuzhou, Jiangsu 221004, PR China; and School of Public Health, Xuzhou Medical College, PR China shows that “HO-1 attenuates hippocampal neurons injury via the activation of BDNF-TrkB-PI3K/Akt signaling pathway in stroke. This study was published, in the July 2  2014 issue of the journal Brain Research,  by Prof  Dong, Qi, and others.

Another study from the Department of Pharmacology, Second Military Medical University, Shanghai, China; Department of Science and Education, Shandong Provincial Hospital affiliated to Shandong University, Jinan, China; and Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China (C.-Y.M.) shows that “Regenerative Neurogenesis After Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide Cascade” This study was published, in the June 9 2015 issue of the journal Stroke,  by Prof  Miao CY, Zhao Y, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Erythropoietin/Haematopoietin-derived peptide functions as a stroke medicine: Cyclic helix B peptide (CHBP), derived from Erythropoietin/Haematopoietin,  attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits, via up-regulation of its target genes BDNF and NAMPT


From research findings to therapeutic opportunity: 

Erythropoietin/Haematopoietin has recently been shown to attenuate stroke. However, the mechanism of action remains largely obscure. Cyclic helix B peptide (CHBP) is derived from Erythropoietin/HaematopoietinThis study suggests, first the first time, that Cyclic helix B peptide (CHBP), by increasing the expression of its target genes, it may: (1) increase the expression of BDNF and NAMPT (Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide); (2) augment neuronal–BDNF-TrkB-PI3K/Akt–survival pathway; (3) increase sirtuins expression; (4) enhance neural stem cells; (5) promote neural functional recovery; (6) attenuate cerebral /Ischemia-reperfusion injury; (7) inhibit neuronal apoptosis; (8) improve learning and memory.

Figure 1. Mechanistic insights into how Cyclic helix B peptide (CHBP) protects against stroke. CHBP protects against stroke via upregulation of its target gene BDNF (Brain-derived growth factor) and NAMPT

Figure 2. Cyclic helix B peptide (CHBP) prevents stroke through induction of Brain-derived growth factor (BDNF) and NAMPT.

 

Together, this study suggests that CHBP may alleviate stroke, and other neurodegenerative diseases (such as multiple sclerosis, cerebral ataxia etc.), promote brain repair and extend the lifespan of an individual. Thus, Cyclic helix B peptide (CHBP),  either alone or in combination with other drugs,” may be used to treat stroke and other neurological deficits (Figs.1-2).  [easy_payment currency=”USD”]  

 

Details of the idea posted: 

Idea Proposed/Formulated by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $500#

Undisclosed mechanistic information: How does Cyclic helix B peptide (CHBP)  increase the expression of BDNF and NAMPT?

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References:  

Citation: Boominathan, L., Erythropoietin/Haematopoietin-derived peptide functions as a stroke medicine: Cyclic helix B peptide (CHBP), derived from Erythropoietin/Haematopoietin,  attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits, via up-regulation of its target genes BDNF and NAMPT, 24/April/2019, 5.55 am,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

 

Comments are closed.